EPO plus radiotherapy does not improve local-regional control in anemic patients with head and neck cancer

the ONA take:

According to a long-term analysis of a study originally published in 2007, researchers have found that the combination of erythropoietin and radiation therapy did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiotherapy or chemoradiotherapy.

The 2007 Radiation Therapy Oncology Group (RTOG) 9903 study was an open-label, randomized, phase III trial that evaluated whether the addition of erythropoietin to radiotherapy would improve disease control in anemia patients with head and neck squamous cell carcinoma.

For this long-term analysis, results showed that the local-regional failure rate was 39.4% for patients who received radiotherapy or chemoradiotherapy without erythropoietin compared with 46.2% for patients who received erythropoietin at 5-year follow-up (HR = 1.40). Researchers found no statistically significant differences in 5-year progression-free survival, overall survival, or 5-year distant metastases rate between the two groups.

The findings suggest that erythropoietin should not be utilized in anemic patients with head and neck squamous cell carcinoma.

EPO plus RT does not improve local-regional control in anemic patients with head and neck cancer
Combination erythropoietin and radiation therapy did not improve control for anemic patients with head and neck squamous cell carcinoma.
Long-term analysis of RTOG 9903 demonstrates that the addition of erythropoietin did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiation therapy or chemoradiation.
READ FULL ARTICLE From Medical Express
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs